Sector footprint
$46.9M in exports
Reported chemicals exports in 2024 across 27 qualifying HS6 products.
Sector export playbook ยท HS 28-38
Guatemala Chemicals exports
where capability meets demand
Explore Guatemala's HS 28-38 product portfolio, buyer markets, growth signals, and diversification opportunities. Use this guide to prioritize research, not to treat calculated indicators as guaranteed sales.
Sector exports$46.9M2024 reported value
Products27Qualifying HS6 products
Buyer markets24Markets represented
Average CAGR+10.6%Product-level growth signal
Global sector size$453.3BReported buyer imports
Chemicals capability
How strong is Guatemala in this sector?
Compare exporter scale with product breadth, buyer demand, growth, and destination reach. A large sector does not remove the need for product, compliance, pricing, and buyer validation.
Global demand
$453.3B buyer imports
The sector's reported buyer import base provides context for product and market prioritization.
How to use the guide
Find the next credible move
Start with products that combine demand and exporter capability, then validate standards, route economics, buyers, and competition.
Product portfolio
Which products anchor the sector?
Each HS6 product is ranked by calculated opportunity and shown with reported market size, exporter exports, growth, and destination reach.
| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
|---|---|---|---|---|---|---|
| HS 300490Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $280.6B | $7.8M | $100.4B | -12.6% | 19 | +0.0% |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $30.4B | $1.2M | $16.7B | +36.3% | 7 | +0.0% |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | $23.5B | $903.0K | $15.0B | +2.2% | 7 | +0.0% |
| HS 330210Odoriferous substances and mixtures: of a kind used in the food or drink industries | $8.5B | $28.1M | $10.9B | +11.3% | 4 | +0.3% |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $25.4B | $653.5K | $10.9B | +24.6% | 8 | +0.0% |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $13.7B | $23.1K | $6.4B | +19.7% | 3 | +0.0% |
| HS 382200Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $13.5B | $114.9K | $5.4B | +4.9% | 4 | +0.0% |
| HS 330300Perfumes and toilet waters | $6.6B | $1.6M | $4.1B | +12.8% | 2 | +0.0% |
| HS 293499Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $7.6B | $576.0 | $3.9B | -7.1% | 2 | +0.0% |
| HS 382600Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $4.3B | $736.7 | $3.4B | +18.2% | 2 | +0.0% |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $3.5B | $9.2K | $3.2B | +171.5% | 1 | +0.0% |
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $8.0B | $1.1K | $2.9B | -3.3% | 1 | +0.0% |
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $2.9K | $2.2B | -18.4% | 2 | +0.0% |
| HS 340220Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $2.3B | $5.8M | $2.1B | +4.7% | 2 | +0.3% |
| HS 300420Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.3K | $2.0B | -2.9% | 1 | +0.0% |
| HS 382319Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $45.9K | $1.9B | +20.6% | 1 | +0.0% |
| HS 380893Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $113.0K | $1.7B | +91.8% | 1 | +0.0% |
| HS 300290Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $3.9B | $38.6K | $1.7B | +9.8% | 2 | +0.0% |
| HS 290110Acyclic hydrocarbons: saturated | $916.4M | $1.7K | $1.3B | +20.4% | 1 | +0.0% |
| HS 294190Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $16.1K | $990.0M | +31.8% | 1 | +0.0% |
| HS 293339Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $1.6B | $157.8K | $871.0M | +54.7% | 1 | +0.0% |
| HS 300449Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | $1.5B | $269.3K | $841.2M | +30.1% | 1 | +0.0% |
| HS 330290Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $1.3B | $35.6K | $803.3M | +15.2% | 1 | +0.0% |
| HS 293399Heterocyclic compounds: n.e.c. in headings no. 2933 | $734.9M | $7.0K | $798.7M | +13.4% | 1 | +0.0% |
| HS 380891Insecticides: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $1.6B | $361.8 | $713.1M | +8.1% | 1 | +0.0% |
| HS 284440Radioactive elements, isotopes, compounds, n.e.c. in heading no. 2844 alloys, dispersions (including cermets), ceramic products and mixtures containing these elements, isotopes or compounds: radioactive residues | $927.2M | $451.2 | $685.2M | -10.2% | 1 | +0.0% |
| HS 340600Candles, tapers and the like | $1.0B | $2.7K | $640.9M | -0.8% | 1 | +0.0% |
Best markets
Where does sector demand concentrate?
Markets are ranked by calculated opportunity across the qualifying products in this sector view.
USA
USA, Puerto Rico and US Virgin Islands
18 products represented in the sector.
$56.0B$145.1B reported buyer importsCHE
Switzerland, Liechtenstein
3 products represented in the sector.
$33.9B$54.6B reported buyer importsDEU
Germany
10 products represented in the sector.
$19.4B$54.8B reported buyer importsCHN
China
4 products represented in the sector.
$10.1B$19.3B reported buyer importsESP
Spain
5 products represented in the sector.
$9.5B$17.7B reported buyer importsCAN
Canada
6 products represented in the sector.
$9.0B$13.3B reported buyer importsFRA
France
6 products represented in the sector.
$8.8B$20.4B reported buyer importsBEL
Belgium
2 products represented in the sector.
$8.2B$20.1B reported buyer importsMEX
Mexico
3 products represented in the sector.
$6.9B$8.3B reported buyer importsNLD
Netherlands
1 products represented in the sector.
$5.3B$10.5B reported buyer importsITA
Italy
1 products represented in the sector.
$4.9B$14.7B reported buyer importsJPN
Japan
2 products represented in the sector.
$4.4B$13.1B reported buyer importsGrowth stars
Which products show the strongest growth?
Average product-level CAGR is a screening signal. Confirm the latest trend, base effects, buyer quality, and commercial feasibility before acting.
| Product | Average CAGR | Opportunity | Markets |
|---|---|---|---|
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | +171.5% | $3.2B | 1 |
| HS 380893Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | +91.8% | $1.7B | 1 |
| HS 293339Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | +54.7% | $871.0M | 1 |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | +36.3% | $16.7B | 7 |
| HS 294190Antibiotics: n.e.c. in heading no. 2941 | +31.8% | $990.0M | 1 |
| HS 300449Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | +30.1% | $841.2M | 1 |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | +24.6% | $10.9B | 8 |
| HS 382319Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | +20.6% | $1.9B | 1 |
| HS 290110Acyclic hydrocarbons: saturated | +20.4% | $1.3B | 1 |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | +19.7% | $6.4B | 3 |
Diversification opportunities
Which products reach the widest buyer base?
Destination count is a simple breadth indicator. It does not measure destination concentration or guarantee resilience.
HS 300490
Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
19 markets$100.4B calculated opportunityHS 330499
Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations)
8 markets$10.9B calculated opportunityHS 300212
Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions
7 markets$16.7B calculated opportunityHS 382499
Chemical products, mixtures and preparations: n.e.c. heading 3824
7 markets$15.0B calculated opportunityHS 330210
Odoriferous substances and mixtures: of a kind used in the food or drink industries
4 markets$10.9B calculated opportunityHS 382200
Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material
4 markets$5.4B calculated opportunityHS 300439
Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale
3 markets$6.4B calculated opportunityHS 330300
Perfumes and toilet waters
2 markets$4.1B calculated opportunityFrequently asked questions
Using the Chemicals export playbook
Practical guidance for interpreting sector scale, growth, product breadth, and buyer markets.
How strong is Guatemala in this sector?
Compare sector exports, product breadth, buyer markets, growth, and global demand. These signals identify research priorities rather than guarantee market access.
What are growth stars?
Products with higher average reported growth in the screened rows. Validate the time period, base effects, buyer demand, and current exporter position.
What does diversification mean here?
Products reaching more buyer markets in the screened data. Destination breadth is useful context but does not replace concentration, route, or buyer analysis.
Data source
OECD trade statistics with CEPII context
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.